deeptech Value proposition
On a mission to advance epicutaneous immunotherapy using our innovative technology platform, ViaskinTM
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, ViaskinTM, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.
Allergy, Food and pediatric allergy, and Specific immunotherapyOriginal language
On a mission to advance epicutaneous immunotherapy using our innovative technology platform, ViaskinTM
DBV Technologies is opening up a decisive new approach to the treatment of food allergy demonstrating a significant level of protection, and is associated with an unprecedented safety profile and level of convenience.
DBV Technologies has developed a unique, proprietary, worldwide-patented technology, the Viaskin® patch. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need.
DBV Technologies collaborates closely in its clinical and preclinical programs with the leaders experts in food allergies around the world to be The Expert in Food Allergy through a new mechanism of action with a proprietary technology.
DBV Technologies | Dedicated to Improving the Lives of Patients with Food Allergies and Other Immunological Diseases
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
https://dbv-technologies.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 7 Oct 2022 | | |